BJH - volume 12, issue 5, september 2021
B. Heyrman MD
The general poor prognosis of AML has stimulated the haematology society and industry to move forward in recent years. Because of these efforts, you could easily imagine yourself at a myeloma session during EHA2021. For patients non-eligible for intensive chemotherapy, the therapeutic arsenal has never been so wide and is constantly expanding. In Belgium, haematologists are bound to strict regulations making ‘game-changing’ data scarce at international congresses. However, the experts in the field shared their strategies in daily practice, which might be even more useful. Nevertheless, one rule remains that it is our duty to include patients in clinical trials whenever possible.
(BELG J HEMATOL 2021;12(5):197-200)
Read moreBJH - volume 12, issue 5, september 2021
C. Hermans MD, PhD, K. Peerlinck MD, PhD, A. Gadisseur MD, PhD, P. Quoc MD, V. Mondelaers MD, P. Maes MD, C. Van Geet MD, PhD
The aim of this non-interventional, observational study conducted in haemophilia B patients in Belgium was to collect real-world data to confirm the efficacy and safety of rIX-FP established in pivotal clinical trials.
(BELG J HEMATOL 2021;12(5):203-6)
Read moreBJH - volume 12, issue 5, september 2021
C. Graux MD, PhD
The EHA congress is not only the opportunity to present or update the results of clinical trials, but it is also the occasion to present some fundamental research and to discuss certain themes that allow us rethinking the overall treatment strategy and monitoring of haematologic diseases.
(BELG J HEMATOL 2021;12(5):207-10)
Read moreBJH - volume 12, issue 5, september 2021
M. Maerevoet MD
How could you select the best of the EHA meeting? A lot of teams presented very exciting work. In this overview I do not pretend to aim to summarise the entire meeting, I am simply reporting selected presentations, remarkable from my point of view.
(BELG J HEMATOL 2021;12(5):213-6)
Read moreBJH - volume 12, issue 5, september 2021
N. Meuleman MD, PhD, M. Vercruyssen MD
Major progress has been made in the treatment of Multiple Myeloma (MM) and new current standard of care has been recently published and includes the introduction of triplet and quadruplet combinations, even in first-line, and the concept of continuous treatment.1 Several new drugs and new associations have been approved and have considerably improved the prognosis of the patients. However, MM remains an incurable disease and patients with high-risk (HR) disease will still experience early relapse. During the European Hematology Association’s annual congress (EHA 2021), results from different trials have highlighted the best options for HR MM, the role of autologous stem cell transplantation, and the exciting results of new anti BCMA-targeting therapy, and have confirmed the results of daratumumab based therapy in first-line treatment.
(BELG J HEMATOL 2021;12(5):220-2)
Read moreBJH - volume 12, issue 5, september 2021
G. Verhoef MD, PhD
Chronic myeloid leukaemia (CML) received a lot of interest at EHA 2021. New ELN recommendations for CML management were presented, which highlighted the importance of risk stratification and cytogenetic analysis. The primary analysis of the phase II OPTIC study concluded that ponatinib showed dose-escalated efficacy in CML patients who were resistant to second-generation tyrosine kinase inhibitors (TKIs). Additionally, final analysis of the EURO-SKI trial revealed that TKI cessation might be appropriate in some CML patients. The Harmony Plus project shed light on the genetic heterogeneity of advanced CML. Finally, mutations in mitochondrial DNA were found to be associated with response to treatment with imatinib. The most important messages of these different presentations will be discussed in this article.
(BELG J HEMATOL 2021;12(5):225-7)
Read moreBJH - volume 12, issue 5, september 2021
M-C. Vekemans MD
Unfortunately, due to the COVID-19 pandemic and for the second consecutive year, the 26th Annual EHA Meeting turned to a full virtual edition. Despite the fact that we were not able to meet and share this event with our colleagues, the content of this edition was outstanding, with many live sessions covering numerous haematological innovations. We selected twelve interesting abstracts that will probably change our daily practice in the near future.
(BELG J HEMATOL 2021;12(5):230-9)
Read more
Top
